Company Information

  

Address: 215 FIRST STREET  
City: CAMBRIDGE 
State: MA 
Zip Code: 02142 
Telephone: 617-299-8380 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system, or CNS, disorders, where there are no approved therapies or existing therapies are inadequate. We have a portfolio of product candidates with a current focus on modulating two critical CNS receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. We are targeting CNS indications where patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-7.25NAN/E
12/2017-7.09NAN/E
09/2017-6.92NAN/E
06/2017-6.10NAN/E
03/2017-5.30NAN/E
12/2016-4.75NAN/E
09/2016-4.20NAN/E
06/2016-3.88NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.25Total Liab/Total Assets0.10
Net Inc/Total Assets-0.51Total Liab/Inv Cap0.11
Net Inc/Inv Cap-0.57Total Liab/Comm Equity0.05
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio10.11
Inventory TurnoverNACurrent Ratio10.11
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 28.85 19.56 16.09 14.95
Operating Income -78.12 -70.45 -74.37 -70.85
Interest Exp NA NA NA NA
Pretax Income -74.60 -69.42 -73.72 -70.20
Other Income 3.52 1.03 0.65 0.65
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -74.60 -69.42 -73.72 -70.20

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 1,083.51 518.85 243.45 285.93
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 1,095.09 525.08 248.34 291.12
Net Property, Plant & Equipment 4.30 4.01 1.89 1.44
Total Assets 1,100.65 529.94 251.09 293.41
Liabilities        
Accounts Payable 37.87 51.95 49.84 32.28
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 37.87 51.95 49.84 32.28
Long-Term Debt NA NA NA NA
Total Liabilities 41.38 54.46 51.03 33.11
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.00 0.00
Retained Earnings -665.05 -590.45 -521.03 -447.31
Treasury Stock -0.21 -0.11 -0.02 -0.02
Total Stockholders' Equity 1,059.28 475.48 200.05 260.30
Total Liabilities and Stockholders' Equity 1,100.65 529.94 251.09 293.41

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -78.57 -58.90 -46.09 -59.08
Net Cash Provided by Investing Activities -312.80 -104.60 43.87 44.31
Net Cash Provided by Financing Activities 643.11 334.82 3.69 2.76

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-18.28--
12/20140.00-33.81-1.67
12/20150.00-94.50-3.40
12/20160.00-158.99-4.75
12/20170.00-270.12-7.09
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/1828247,562--




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.